Daren K Heyland1, Gunnar Elke2, Deborah Cook3, Mette M Berger4, Paul E Wischmeyer5, Martin Albert6, John Muscedere7, Gwynne Jones8, Andrew G Day7. 1. Kingston General Hospital, Kingston, Ontario, Canada dkh2@queensu.ca. 2. University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. 3. St Joseph's Healthcare, Hamilton, Ontario, Canada. 4. University Hospital CHUV, Lausanne, Switzerland. 5. University of Colorado School of Medicine, Aurora. 6. Hôpital du Sacré-Coeur de Montreal, Quebec, Canada. 7. Kingston General Hospital, Kingston, Ontario, Canada. 8. Ottawa Hospital, General Campus, Ottawa, Ontario, Canada.
Abstract
BACKGROUND: The recent large randomized controlled trial of glutamine and antioxidant supplementation suggested that high-dose glutamine is associated with increased mortality in critically ill patients with multiorgan failure. The objectives of the present analyses were to reevaluate the effect of supplementation after controlling for baseline covariates and to identify potentially important subgroup effects. MATERIALS AND METHODS: This study was a post hoc analysis of a prospective factorial 2 × 2 randomized trial conducted in 40 intensive care units in North America and Europe. In total, 1223 mechanically ventilated adult patients with multiorgan failure were randomized to receive glutamine, antioxidants, both glutamine and antioxidants, or placebo administered separate from artificial nutrition. We compared each of the 3 active treatment arms (glutamine alone, antioxidants alone, and glutamine + antioxidants) with placebo on 28-day mortality. Post hoc, treatment effects were examined within subgroups defined by baseline patient characteristics. Logistic regression was used to estimate treatment effects within subgroups after adjustment for baseline covariates and to identify treatment-by-subgroup interactions (effect modification). RESULTS: The 28-day mortality rates in the placebo, glutamine, antioxidant, and combination arms were 25%, 32%, 29%, and 33%, respectively. After adjusting for prespecified baseline covariates, the adjusted odds ratio of 28-day mortality vs placebo was 1.5 (95% confidence interval, 1.0-2.1, P = .05), 1.2 (0.8-1.8, P = .40), and 1.4 (0.9-2.0, P = .09) for glutamine, antioxidant, and glutamine plus antioxidant arms, respectively. In the post hoc subgroup analysis, both glutamine and antioxidants appeared most harmful in patients with baseline renal dysfunction. No subgroups suggested reduced mortality with supplements. CONCLUSIONS: After adjustment for baseline covariates, early provision of high-dose glutamine administered separately from artificial nutrition was not beneficial and may be associated with increased mortality in critically ill patients with multiorgan failure. For both glutamine and antioxidants, the greatest potential for harm was observed in patients with multiorgan failure that included renal dysfunction upon study enrollment.
RCT Entities:
BACKGROUND: The recent large randomized controlled trial of glutamine and antioxidant supplementation suggested that high-dose glutamine is associated with increased mortality in critically illpatients with multiorgan failure. The objectives of the present analyses were to reevaluate the effect of supplementation after controlling for baseline covariates and to identify potentially important subgroup effects. MATERIALS AND METHODS: This study was a post hoc analysis of a prospective factorial 2 × 2 randomized trial conducted in 40 intensive care units in North America and Europe. In total, 1223 mechanically ventilated adult patients with multiorgan failure were randomized to receive glutamine, antioxidants, both glutamine and antioxidants, or placebo administered separate from artificial nutrition. We compared each of the 3 active treatment arms (glutamine alone, antioxidants alone, and glutamine + antioxidants) with placebo on 28-day mortality. Post hoc, treatment effects were examined within subgroups defined by baseline patient characteristics. Logistic regression was used to estimate treatment effects within subgroups after adjustment for baseline covariates and to identify treatment-by-subgroup interactions (effect modification). RESULTS: The 28-day mortality rates in the placebo, glutamine, antioxidant, and combination arms were 25%, 32%, 29%, and 33%, respectively. After adjusting for prespecified baseline covariates, the adjusted odds ratio of 28-day mortality vs placebo was 1.5 (95% confidence interval, 1.0-2.1, P = .05), 1.2 (0.8-1.8, P = .40), and 1.4 (0.9-2.0, P = .09) for glutamine, antioxidant, and glutamine plus antioxidant arms, respectively. In the post hoc subgroup analysis, both glutamine and antioxidants appeared most harmful in patients with baseline renal dysfunction. No subgroups suggested reduced mortality with supplements. CONCLUSIONS: After adjustment for baseline covariates, early provision of high-dose glutamine administered separately from artificial nutrition was not beneficial and may be associated with increased mortality in critically illpatients with multiorgan failure. For both glutamine and antioxidants, the greatest potential for harm was observed in patients with multiorgan failure that included renal dysfunction upon study enrollment.
Authors: Vinita Mishra; Malcolm Baines; Sara Elizabeth Perry; Paul Jeremy McLaughlin; Jeff Carson; Richard Wenstone; Alan Shenkin Journal: Clin Nutr Date: 2006-12-14 Impact factor: 7.324
Authors: David Brealey; Michael Brand; Iain Hargreaves; Simon Heales; John Land; Ryszard Smolenski; Nathan A Davies; Chris E Cooper; Mervyn Singer Journal: Lancet Date: 2002-07-20 Impact factor: 79.321
Authors: Daren Heyland; John Muscedere; Paul E Wischmeyer; Deborah Cook; Gwynne Jones; Martin Albert; Gunnar Elke; Mette M Berger; Andrew G Day Journal: N Engl J Med Date: 2013-04-18 Impact factor: 91.245
Authors: W Druml; M Joannidis; S John; A Jörres; M Schmitz; J Kielstein; D Kindgen-Milles; M Oppert; V Schwenger; C Willam; A Zarbock Journal: Med Klin Intensivmed Notfmed Date: 2018-05-03 Impact factor: 0.840
Authors: Thomas R Ziegler; Addison K May; Gautam Hebbar; Kirk A Easley; Daniel P Griffith; Nisha Dave; Bryan R Collier; George A Cotsonis; Li Hao; Traci Leong; Amita K Manatunga; Eli S Rosenberg; Dean P Jones; Gregory S Martin; Gordon L Jensen; Harry C Sax; Kenneth A Kudsk; John R Galloway; Henry M Blumberg; Mary E Evans; Paul E Wischmeyer Journal: Ann Surg Date: 2016-04 Impact factor: 12.969